Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
An Emerging Name in Cannabis: HERB (click to learn more) AI-Driven Wellness Play on the CSE (click to learn more) Golden Cariboo (CSE:GCC) (OTC:GCCFF) Unlocks Cariboo Gold Potential (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Acumen Pharmaceuticals Inc ABOS

Healthcare Biotechnology
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target... see more

Current News (NDAQ:ABOS)

Acumen Pharmaceuticals Highlights Enhanced Brain Delivery(TM) Technology for Oligomer-Selective Antibodies and Recruitment Strategies for Phase 2 ALTITUDE-AD Clinical Trial at 18th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference

GlobeNewswire December 2, 2025

Acumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference

GlobeNewswire November 18, 2025

Acumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People with Early Alzheimer's Disease

GlobeNewswire November 17, 2025

Acumen Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Highlights

GlobeNewswire November 12, 2025

Acumen Pharmaceuticals Appoints George Golumbeski, Ph.D., as Chairman of its Board of Directors

GlobeNewswire November 10, 2025

Acumen Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 12, 2025

GlobeNewswire November 5, 2025

Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

GlobeNewswire November 4, 2025

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire August 26, 2025

Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights

GlobeNewswire August 12, 2025
View More News ››

Opinion & Analysis (NDAQ:ABOS)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ABOS)

Results

Anyone heard how the clinical trials are going?
goldtech - June 1, 2023

RE:RE:Great company with great working capital

agreed, it is a lot of cash on hand.   I think ABOS is perhaps a bit less transparent than PMN since it became publicly traded...
Gbathat - March 2, 2023

RE:Great company with great working capital

The big question here is, where would the SPP of $5.26 US be for "ABOS" if it didn't have $200 Million cash on hand...
G1945V - February 27, 2023

Great company with great working capital

Acumen is an attractive opportunity- addresses a key gap in an enormous market.  My money is on both Acumen and Promis.  Both...
Gbathat - December 7, 2022

ABOS ..... early a.m runner with volume.....

No news Me no position
Iseneschal - September 28, 2022
View more Bullboard ››

Mirasol Resources Ltd.

Mirasol Resources Ltd.

Mirasol Resources Ltd. engages in the acquisition and exploration of mineral properties in Chile and Argentina. The company ...
View More »

Podcasts